[
1. Martinello M, Bajis S, Dore GJ. Progress Toward Hepatitis C Virus Elimination: Therapy and Implementation. Gastroenterol Clin North Am. Published online 2020. doi:10.1016/j.gtc.2020.01.005
]Open DOISearch in Google Scholar
[
2. W.H.O. Combating hepatitis B and C to reach elimination by 2030. Published online 2016.
]Search in Google Scholar
[
3. Thomas DL. Global elimination of chronic hepatitis. N Engl J Med. Published online 2019. doi:10.1056/NEJMra 1810477
]Open DOISearch in Google Scholar
[
4. Haseltine WA. Universal disease screening and treatment - The Egyptian example. N Engl J Med. Published online 2020. doi:10.1056/NEJMp1915818
]Open DOISearch in Google Scholar
[
5. Averhoff F, Shadaker S, Gamkrelidze A, et al. Progress and challenges of a pioneering hepatitis C elimination program in the country of Georgia. J Hepatol. Published online 2020. doi:10.1016/j.jhep.2019.11.019
]Open DOISearch in Google Scholar
[
6. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol. Published online 2017. doi:10.1016/j.jhep.2016.09.001
]Open DOISearch in Google Scholar
[
7. Pawlotsky JM, Negro F, Aghemo A, et al. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. Published online 2018. doi:10.1016/j.jhep.2018.03.026
]Open DOISearch in Google Scholar
[
8. Seo S., Silverberg M.J., Horlung L.B. et al. Prevalence of spontaneous clearence of viral hepatitis C infection doubled from 1998 to 2017. Clin Gastroenterol Hepatol. Published online 2020:18:511-513.10.1016/j.cgh.2019.04.035
]Search in Google Scholar
[
9. Heffernan A, Cooke GS, Nayagam S, Thursz M, Hallett TB. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. Lancet. Published online 2019. doi:10.1016/S0140-6736(18)32277-3
]Open DOISearch in Google Scholar
[
10. Younossi Z, Park H, Henry L, Adeyemi A, Stepanova M. Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden. Gastroenterology. Published online 2016. doi:10.1053/j.gastro.2016.02.03926924097
]Open DOISearch in Google Scholar
[
11. Cacoub P, Comarmond C, Desbois AC, Saadoun D. Rheumatologic Manifestations of Hepatitis C Virus Infection. Clin Liver Dis. Published online 2017. doi:10.1016/j.cld.2017.03.00228689585
]Open DOISearch in Google Scholar
[
12. Goossens N, Negro F. Cardiovascular Manifestations of Hepatitis C Virus. Clin Liver Dis. Published online 2017. doi:10.1016/j.cld.2017.03.00328689586
]Open DOISearch in Google Scholar
[
13. Degasperi E, Aghemo A, Colombo M. Treatment of Extrahepatic Manifestations of Hepatitis C Virus. Clin Liver Dis. Published online 2017. doi:10.1016/j.cld.2017.03.01528689598
]Open DOISearch in Google Scholar
[
14. Facente SN, Burk K, Eagen K, Mara ES, Smith AA, Lynch CS. New Treatments Have Changed the Game: Hepatitis C Treatment in Primary Care. Infect Dis Clin North Am. Published online 2018. doi:10.1016/j.idc. 2018.02.012
]Open DOISearch in Google Scholar
[
15. Arora S, Thornton K, Murata G, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med. Published online 2011. doi:10.1056/NEJMoa1009370382041921631316
]Open DOISearch in Google Scholar
[
16. Schwarz K.B. LH. Viral hepatitis in children. In: Zakim and Boyer’s Hepatology and Boyer’s Hepatology. 7th ed.; 2015:1015-1028.10.1016/B978-0-323-37591-7.00065-3
]Search in Google Scholar
[
17. Nehra V, Rizza SA, Temesgen Z. Sofosbuvir/ velpatasvir fixed-dose combination for the treatment of chronic hepatitis C virus infection. Drugs of Today. Published online 2017. doi:10.1358/dot.2017. 53.3. 2604176
]Open DOISearch in Google Scholar
[
18. Karnsakul W, Schwarz KB. Management of Hepatitis C Infection in children in the era of Direct-acting Antiviral Agents. J Viral Hepat. Published online 2019. doi:10.1111/jvh.1311330980688
]Open DOISearch in Google Scholar
[
19. Indolfi G, Hierro L, Dezsofi A, et al. Treatment of Chronic Hepatitis C Virus Infection in Children: A Position Paper by the Hepatology Committee of European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. Published online 2018. doi:10.1097/MPG.000000000000187229287014
]Open DOISearch in Google Scholar
[
20. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. Published online 2001. doi:10.1056/NEJM20010705345010711439948
]Open DOISearch in Google Scholar
[
21. Rosen HR. Chronic hepatitis C infection. N Engl J Med. Published online 2011. doi:10.1056/NEJMcp100661321696309
]Open DOISearch in Google Scholar
[
22. Gonzalez HC, Gordon SC. Hepatitis C: Does Successful Treatment Alter the Natural History and Quality of Life? Gastroenterol Clin North Am. Published online 2020. doi:10.1016/j.gtc.2020.01.007
]Open DOISearch in Google Scholar
[
23. Ward J.W. HD. Natural history of chronic hepatitis C. In: Zakim and Boyer’s Hepatology. 7th ed. Elsevier; 2018:428-455.10.1016/B978-0-323-37591-7.00029-X
]Search in Google Scholar
[
24. Boldt MD, Brill J V., Davis GL, et al. Hepatitis C Screening: Summary of Recommendations From the Clinical Decision Tool. Gastroenterology. Published online 2013. doi:10.1053/j.gastro.2013.09.007
]Open DOISearch in Google Scholar
[
25. Pawlotsky J.M. Acute viral hepatitis. In: Goldman and Gilman Medicine. 26th ed. Elsevier; 2020:4958-4965.
]Search in Google Scholar
[
26. Beigel J.H. SK. Antiviral therapy (non HIV). In: Goldman and Cecil Medicine. 26th ed. Elsevier; 2020:2140-2158.
]Search in Google Scholar
[
27. Mysore KR, Leung DH. Hepatitis B and C. Clin Liver Dis. Published online 2018. doi:10.1016/j.cld.2018.06.002
]Open DOISearch in Google Scholar
[
28. Clemente MG, Antonucci R, Sotgiu G, Dettori M, Piana A, Vajro P. Present and future management of viral hepatitis B and C in children. Clin Res Hepatol Gastroenterol. Published online 2020. doi:10.1016/j.clinre.2020.02.010
]Open DOISearch in Google Scholar
[
29. Feld JJ, Foster GR. Second generation direct-acting antivirals Do we expect major improvements? J Hepatol. Published online 2016. doi:10.1016/j.jhep.2016.07.007
]Open DOISearch in Google Scholar
[
30. Lampertico P, Carrión JA, Curry M, et al. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis. J Hepatol. Published online 2020. doi:10.1016/j.jhep.2020.01.025
]Open DOISearch in Google Scholar
[
31. Degasperi E, Spinetti A, Lombardi A, et al. Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure. J Hepatol. Published online 2019. doi:10.1016/j.jhep.2019.07.020
]Open DOISearch in Google Scholar
[
32. Petersen J, Olah K, Lorenzen T, et al. Changing landscape of HCV treatment in Germany: Data from a large real-world cohort 2014-2017. J Hepatol. Published online 2018. doi:10.1016/s0168-8278(18)30736-0
]Open DOISearch in Google Scholar
[
33. Spearman CW, Dusheiko GM, Hellard M, Sonderup M. Hepatitis C. Lancet. Published online 2019. doi:10.1016/S0140-6736(19)32320-7
]Open DOISearch in Google Scholar
[
34. Kanwal F, Bacon BR, Beste LA, et al. Hepatitis C Virus Infection Care PathwayA Report From the American Gastroenterological Association Institute HCV Care Pathway Work Group. Gastroenterology. Published online 2017. doi:10.1053/j.gastro.2017.03.039
]Open DOISearch in Google Scholar
[
35. Brown RS, Buti M, Rodrigues L, et al. Glecaprevir/pibrentasvir for 8?weeks in treatment-naïve patients with chronic HCV genotypes 16 and compensated cirrhosis: The EXPEDITION-8 trial. J Hepatol. Published online 2020. doi:10.1016/j.jhep.2019.10.020
]Open DOISearch in Google Scholar
[
36. Jacobson IM, Lawitz E, Gane EJ, et al. Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials. Gastroenterology. Published online 2017. doi:10.1053/j.gastro.2017.03.047
]Open DOISearch in Google Scholar
[
37. Zuckerman E, Gutierrez J, Ustianowski A, et al. THU-198-Efficacy and safety of glecaprevir/pibrentasvir treatment for 8 weeks in treatment-naive patients with chronic hepatitis C virus infection without cirrhosis or with compensated cirrhosis: Analysis of data pooled from phase 2 and 3 studies. J Hepatol. Published online 2019. doi:10.1016/s0618-8278(19)30473-6
]Open DOISearch in Google Scholar
[
38. Baumert TF, Berg T, Lim JK, Nelson DR. Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges. Gastroenterology. Published online 2019. doi:10.1053/j.gastro.2018.10.024644691230342035
]Open DOISearch in Google Scholar
[
39. Dore GJ, Feld JJ, Thompson A, et al. Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. J Hepatol. Published online 2020. doi:10.1016/j. jhep.2019.10.010
]Open DOISearch in Google Scholar
[
40. Vermehren J, Park JS, Jacobson IM, Zeuzem S. Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection. J Hepatol. Published online 2018. doi:10.1016/j.jhep.2018.07.00230006068
]Open DOISearch in Google Scholar
[
41. Ioannou GN, Feld JJ. What Are the Benefits of a Sustained Virologic Response to Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection? Gastroenterology. Published online 2019. doi:10.1053/j.gastro.2018.10.03330367836
]Open DOISearch in Google Scholar
[
42. Wilson E, Covert E, Hoffmann J, et al. A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY). J Hepatol. Published online 2019. doi:10.1016/j.jhep.2019.05.02131173815
]Open DOISearch in Google Scholar
[
43. Araujo A, Valenzuela-Granados V, Lopes AB, Michalczuk MT, Mantovani A, Alvares-da-Silva MR. Sofosbuvir-based antiviral therapy in patients with recurrent HCV infection after liver transplant: A real-life experience. Ann Hepatol. Published online 2019. doi:10.1016/j.aohep.2018.09.00431028014
]Open DOISearch in Google Scholar
[
44. N.L. L, R. G, A. S. Ledipasvir/sofosbuvir therapy is safe and effective in liver transplant recipients with recurrent HCV infection: Single center, real life experience. J Hepatol. Published online 2016.
]Search in Google Scholar
[
45. Farum R., Wang H., Thomson L. et al. Previous exposure to hepatitis B infection and liver outcome in population with hepatitis C. Gut. Published online 2015:64(suppl 1) A39-A40 (abs).10.1136/gutjnl-2015-309861.79
]Search in Google Scholar
[
46. Abdelaal R, Yanny B, El Kabany M. HBV/HCV Coinfection in the Era of HCV-DAAs. Clin Liver Dis. Published online 2019. doi:10.1016/j.cld.2019.04.00331266620
]Open DOISearch in Google Scholar
[
47. Chien RN, Kao JH, Peng CY, et al. Taiwan consensus statement on the management of chronic hepatitis B. J Formos Med Assoc. Published online 2019. doi:10.1016/j.jfma.2018.11.00830527436
]Open DOISearch in Google Scholar
[
48. Cacoub P, Desbois AC, Comarmond C, Saadoun D. Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: A meta-analysis. Gut. Published online 2018. doi:10.1136/gutjnl-2018-31623429703790
]Open DOISearch in Google Scholar
[
49. Martin P, Fabrizi F. Editorial: Benefit of Direct-Acting Antiviral Therapy for Cryoglobulinemia due to Hepatitis C Infection. Am J Gastroenterol. Published online 2017. doi:10.1038/ajg.2017.19928766566
]Open DOISearch in Google Scholar
[
50. Petta S, Craxì A. Extrahepatic Manifestations of Chronic Viral C Hepatitis. Gastroenterol Clin North Am. Published online 2020. doi:10.1016/j.gtc.2020.01.01232389367
]Open DOISearch in Google Scholar
[
51. Wong RJ, Saab S, Ahmed A. Extrahepatic Manifestations of Hepatitis C Virus After Liver Transplantation. Clin Liver Dis. Published online 2017. doi:10.1016/j.cld.2017.03.01328689596
]Open DOISearch in Google Scholar
[
52. Aghemo A, Colombo M. Glecaprevir/Pibrentasvir: The Final Piece in the Hepatitis C Virus Treatment Puzzle? Gastroenterology. Published online 2018. doi:10.1053/j.gastro.2018.01.03529406265
]Open DOISearch in Google Scholar
[
53. Roediger A, Wilsdon T, Haderi A, Pendleton K, Azais B. Competition between on-patent medicines in Europe. Health Policy (New York). Published online 2019. doi:10.1016/j.healthpol.2019.05.00931176459
]Open DOISearch in Google Scholar